Overall response rate was 40.3% (N= 896/2221) with a total of N=361 in the short-, N=251 in the mid-, and N=284
in the long-term group returning questionnaires. Mean follow up was 23.3 ± 7.2 months for short-, 49.8 ± 9.1
months for mid-, and 147.9 ± 20.6 months for long-term. Differences were significant for age (short: 60.9±11.6, mid:
60.3 ± 12.5, long: 58.4±10.5, p=0.03), smoking status, prior prolapse surgery, and perioperative vaginal estrogen use
(all p<0.05). No differences in race, body mass index, medical comorbidities (COPD), parity with mode of delivery, and
menopausal status were seen among groups. Treatment success differed among groups: 75.4% in the short-, 62.3%
mid-, and 67.0% long-term groups, p<0.01. There was no difference in treatment success between mid- and long-term
follow-up groups (p=0.28). Logistic regression showed that women with mid- or long-term follow-up were nearly half as
likely as their short-term counterparts to report subjective treatment success, adjusted odds ratio 0.51 (95% Confidence
Interval: 0.36, 0.74) controlling for potential confounding factors (age, race, BMI categories, comorbidities, smoking,
mode of delivery, prior or concurrent pelvic surgeries, and type of sling). Median UDI-6 and PFIQ-7 scores as well as
PGI-I differed significantly across short-, mid- and long-term follow-up groups (all p<0.01,Table). Patient satisfaction
was similar: “completely” and “somewhat satisfied” in 83.3% short-, 76.6% mid-, 78.2% long-term follow-up (p = 0.09).
In the long-term group, 73.1% reported they would undergo a MUS again.